Cerebrospinal Fluid Biomarkers Can Play a Pivotal Role in the Diagnostic Work Up of Primary Progressive Aphasia
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Three variants of primary progressive aphasia (PPA) have been currently characterized: non fluent/agrammatic (nfv-PPA), semantic (sv-PPA), and logopenic variant (lv-PPA). lv-PPA is most commonly associated with Alzheimer's disease (AD), while nfv-PPA and sv-PPA are related to frontotemporal lobar degeneration. Objective: We aimed to determine whether cerebrospinal fluid (CSF) amyloid-β42 (Aβ 42 ), total tau protein (t-tau), and phosphorylated tau (p-tau), frequently abnormal in AD, could constitute a useful tool in the PPA diagnostic work up, in order to identify subjects with an underlying AD pathology. Methods: We measured CSF biomarker levels in a group of twenty-eight patients, fourteen lv-PPA, nine nfv-PPA, and five sv-PPA. Results: Since there were no significant differences in any of the parameters investigated between nfv-PPA and sv-PPA, the two groups were considered as one (nfv/sv-PPA). At diagnosis, lv-PPA were older than nfv/sv-PPA patients (mean values: 70.7 versus 64.6 years, p = 0.02). CSF biomarker mean concentrations were significantly different in lv-PPA versus nfv/sv-PPA patients (p = 0.000): Aβ 42 350.64 versus 661.64 ng/L; tau 631.21 versus 232.71 ng/L; p-tau 101 versus 38.21 ng/L. According to the recent AD diagnostic criteria, (Cummings et al., 2013) eleven lv-PPA and only one nfv/sv-PPA showed a liquoral pattern typical for AD. Finally lv-PPA had CSF biomarker levels very similar to a sample of 72 AD patients from our Department. Conclusions: Our data showed that CSF biomarkers can easily and reliably detect those patients with language disorders due to an underlying AD pathology, thus offering the possibility of targeted therapeutic interventions. However, because of the small sample size, such analyses should be reproduced in larger populations of patients to confirm our data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 2×
“Considering the groups altogether, there was a negative correlation between CSF tau and MMSE, as already observed in previous studies [33, 35].”
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“We considered as pathological (or AD indicative) A 42 concentrations below 500 ng/l, tau and p-tau concentrations greater than 500 ng/l and 60 ng/l respectively, as indicated in major international works [16, 17].”
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · cited 1×
“Since CSF p-tau reflects a central process in neurofibrillary tangle formation and is a very specific marker of AD pathology [38], it was unexpected that its mean values correlated with disease severity even in nfv/svPPA patients.”
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 1×
“Since CSF A 42 is an index of cerebral amyloid burden [28, 29], these patients probably presented a pathological cerebral amyloid accumulation, a typical AD finding.”
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
The evolution and pathology of frontotemporal dementia
Kertesz, A., McMonagle, P., Blair, M., Davidson, W., & Munoz, D. G. (2005) · Brain · doi:10.1093/brain/awh598 · Cited by 609
Focal cortical presentations of Alzheimer's disease
Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581 · cited 2×
“Conversely, lv-PPA is more frequently associated with Alzheimer’s disease (AD) (amyloid plaques and neurofibrillary tangles) [5, 6].”
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia
Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Léger, G. C., Rademaker, A., Weintraub, S., & Bigio, E. H. (2008) · Annals of Neurology · doi:10.1002/ana.21388 · Cited by 513
Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia
Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., O'Neil, J. P., Lal, R. A., Dronkers, N. F., Miller, B. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21451 · Cited by 477 · cited 1×
“Taken together, our data seem to confirm that lv-PPA usually shares AD pathology, as shown by anatomo-pathological [5, 6] or PIB-PET scan [31] studies, while nfv-PPA and sv-PPA mostly belong to FTD spectrum, as found in other recent pathological series [3, 4].”
Cited by
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia
Bergeron, D., Gorno‐Tempini, M. L., Rabinovici, G. D., Santos‐Santos, M. A., Seeley, W., Miller, B. L., Pijnenburg, Y., Keulen, M. A., Groot, C., van Berckel, B. N. M., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25333 · Cited by 203
Self-citationBiomarkers for diseases with TDP-43 pathology
Steinacker, P., Barschke, P., & Otto, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.10.003 · Cited by 57
Louwersheimer, E., Keulen, M. A., Steenwijk, M. D., Wattjes, M. P., Jiskoot, L. C., Vrenken, H., Teunissen, C. E., van Berckel, B. N. M., van der Flier, W. M., Scheltens, P., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150812 · Cited by 46
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update
Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13669 · Cited by 30
Metadata
- Authors
- Santangelo, R., Coppi, E., Ferrari, L., Bernasconi, M. P., Pinto, P., Passerini, G., Comi, G., & Magnani, G.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2014-12-23
- Volume
- 43
- Issue
- 4
- Pages
- 1429-1440
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1553615263
- Cited by
- 29
- References
- 11
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.